JP2008506708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008506708A5 JP2008506708A5 JP2007521673A JP2007521673A JP2008506708A5 JP 2008506708 A5 JP2008506708 A5 JP 2008506708A5 JP 2007521673 A JP2007521673 A JP 2007521673A JP 2007521673 A JP2007521673 A JP 2007521673A JP 2008506708 A5 JP2008506708 A5 JP 2008506708A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- aminomethyl
- phenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 119
- -1 aryl (C 1-10 ) alkyl Chemical group 0.000 claims 76
- 150000001875 compounds Chemical class 0.000 claims 58
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 125000005842 heteroatom Chemical group 0.000 claims 46
- 125000000753 cycloalkyl group Chemical group 0.000 claims 44
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 36
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 33
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 32
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 31
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000004104 aryloxy group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- PBOZNYRGRFQUIM-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1Br PBOZNYRGRFQUIM-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- GHNOPDKEEAXOFX-UHFFFAOYSA-N 2,7-diamino-6-(1-aminoethyl)-5-(2-chloro-5-fluorophenyl)-3-methylpyrido[2,3-d]pyrimidin-4-one Chemical compound CC(N)C1=C(N)N=C2N=C(N)N(C)C(=O)C2=C1C1=CC(F)=CC=C1Cl GHNOPDKEEAXOFX-UHFFFAOYSA-N 0.000 claims 1
- YYXIAIHZOQWCIZ-UHFFFAOYSA-N 2-[6-(aminomethyl)-1,3,7-trimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound NCC=1C(C)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC(F)=CC=C1C#N YYXIAIHZOQWCIZ-UHFFFAOYSA-N 0.000 claims 1
- FOQRWMXKHJTMRG-UHFFFAOYSA-N 2-[6-(aminomethyl)-1,3-dimethyl-2,4-dioxo-7-(2,2,2-trifluoroethylamino)pyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(NCC(F)(F)F)=C(CN)C=1C1=CC(F)=CC=C1C#N FOQRWMXKHJTMRG-UHFFFAOYSA-N 0.000 claims 1
- SBXLTVLZUDWGAH-UHFFFAOYSA-N 2-[6-(aminomethyl)-1,3-dimethyl-2,4-dioxo-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(C(F)(F)F)=C(CN)C=1C1=CC(F)=CC=C1C#N SBXLTVLZUDWGAH-UHFFFAOYSA-N 0.000 claims 1
- YNCWECQLJKSAKV-UHFFFAOYSA-N 2-[6-(aminomethyl)-1,3-dimethyl-2,4-dioxo-7-pyrrolidin-1-ylpyrido[2,3-d]pyrimidin-5-yl]-5-chlorobenzonitrile Chemical compound NCC=1C(C=2C(=CC(Cl)=CC=2)C#N)=C2C(=O)N(C)C(=O)N(C)C2=NC=1N1CCCC1 YNCWECQLJKSAKV-UHFFFAOYSA-N 0.000 claims 1
- UCPJRWMTPLQOPJ-UHFFFAOYSA-N 2-[6-(aminomethyl)-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC=C(CN)C=1C1=CC(F)=CC=C1C#N UCPJRWMTPLQOPJ-UHFFFAOYSA-N 0.000 claims 1
- QFDZRYGQHHPCTI-UHFFFAOYSA-N 2-[6-(aminomethyl)-3-(cyclopropylmethyl)-1,7-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-5-chlorobenzonitrile Chemical compound O=C1C=2C(C=3C(=CC(Cl)=CC=3)C#N)=C(CN)C(C)=NC=2N(C)C(=O)N1CC1CC1 QFDZRYGQHHPCTI-UHFFFAOYSA-N 0.000 claims 1
- NAVFRWGPYJGCQW-UHFFFAOYSA-N 2-[6-(aminomethyl)-7-[bis(trifluoromethyl)amino]-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N(C(F)(F)F)C(F)(F)F)=C(CN)C=1C1=CC(F)=CC=C1C#N NAVFRWGPYJGCQW-UHFFFAOYSA-N 0.000 claims 1
- SGGHBAVUMJDAEM-UHFFFAOYSA-N 2-[6-(aminomethyl)-7-chloro-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(Cl)=C(CN)C=1C1=CC(F)=CC=C1C#N SGGHBAVUMJDAEM-UHFFFAOYSA-N 0.000 claims 1
- PTUZDYBWBWNURF-UHFFFAOYSA-N 2-[6-(aminomethyl)-7-ethoxy-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-5-chlorobenzonitrile Chemical compound NCC=1C(OCC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC=C(Cl)C=C1C#N PTUZDYBWBWNURF-UHFFFAOYSA-N 0.000 claims 1
- ZSXQRILDNYNHAX-UHFFFAOYSA-N 2-[6-(aminomethyl)-7-methoxy-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-5-chlorobenzonitrile Chemical compound NCC=1C(OC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC=C(Cl)C=C1C#N ZSXQRILDNYNHAX-UHFFFAOYSA-N 0.000 claims 1
- VFPBKHMUTLLLAE-UHFFFAOYSA-N 2-[7-amino-6-(aminomethyl)-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1C#N VFPBKHMUTLLLAE-UHFFFAOYSA-N 0.000 claims 1
- BPVOKDDONNBGTD-UHFFFAOYSA-N 2-[7-amino-6-(aminomethyl)-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC=C1C#N BPVOKDDONNBGTD-UHFFFAOYSA-N 0.000 claims 1
- IGLZUUDBLGOTDT-UHFFFAOYSA-N 5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-2,4,7-trioxo-8h-pyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(O)=C(C#N)C=1C1=CC(F)=CC=C1Br IGLZUUDBLGOTDT-UHFFFAOYSA-N 0.000 claims 1
- LNLBAJHYXLTXRD-UHFFFAOYSA-N 5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-7-morpholin-4-yl-2,4-dioxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound N#CC=1C(C=2C(=CC=C(F)C=2)Br)=C2C(=O)N(C)C(=O)N(C)C2=NC=1N1CCOCC1 LNLBAJHYXLTXRD-UHFFFAOYSA-N 0.000 claims 1
- ITURIGSYOOMUAV-UHFFFAOYSA-N 5-(2-bromo-5-fluorophenyl)-7-chloro-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(Cl)=C(C#N)C=1C1=CC(F)=CC=C1Br ITURIGSYOOMUAV-UHFFFAOYSA-N 0.000 claims 1
- VFPRFVSEPLFKAI-UHFFFAOYSA-N 6-(aminomethyl)-3-benzyl-5-(2-chloro-3,5-difluorophenyl)-1-methyl-7-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(CC=3C=CC=CC=3)C(=O)N(C)C2=NC(C(F)(F)F)=C(CN)C=1C1=CC(F)=CC(F)=C1Cl VFPRFVSEPLFKAI-UHFFFAOYSA-N 0.000 claims 1
- KLZQPRPXUFHTTA-UHFFFAOYSA-N 6-(aminomethyl)-3-benzyl-5-(4-chloro-2-methoxyphenyl)-1-methyl-7-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=CC(Cl)=CC=C1C1=C(CN)C(C(F)(F)F)=NC2=C1C(=O)N(CC=1C=CC=CC=1)C(=O)N2C KLZQPRPXUFHTTA-UHFFFAOYSA-N 0.000 claims 1
- FLOKCOVNZXIQPN-UHFFFAOYSA-N 6-(aminomethyl)-5-(2,4-dichlorophenyl)-1,3-dimethyl-7-(methylamino)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(NC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC=C(Cl)C=C1Cl FLOKCOVNZXIQPN-UHFFFAOYSA-N 0.000 claims 1
- MCNSYOCSWOKACY-UHFFFAOYSA-N 6-(aminomethyl)-5-(2,4-dichlorophenyl)-1,3-dimethyl-8h-pyrido[2,3-d]pyrimidine-2,4,7-trione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(O)=C(CN)C=1C1=CC=C(Cl)C=C1Cl MCNSYOCSWOKACY-UHFFFAOYSA-N 0.000 claims 1
- ROJWXYBULXPBKW-UHFFFAOYSA-N 6-(aminomethyl)-5-(2,4-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC=C(CN)C=1C1=CC=C(Cl)C=C1Cl ROJWXYBULXPBKW-UHFFFAOYSA-N 0.000 claims 1
- QXVLCIVEIASULH-UHFFFAOYSA-N 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-(dimethylamino)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(N(C)C)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC=C(Cl)C=C1Cl QXVLCIVEIASULH-UHFFFAOYSA-N 0.000 claims 1
- YOJMMUNVHSHXMC-UHFFFAOYSA-N 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-(ethylamino)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(NCC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC=C(Cl)C=C1Cl YOJMMUNVHSHXMC-UHFFFAOYSA-N 0.000 claims 1
- IDKCTEQTCQCYNX-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-3,5-difluorophenyl)-1,3-dimethyl-7-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(C(F)(F)F)=C(CN)C=1C1=CC(F)=CC(F)=C1Br IDKCTEQTCQCYNX-UHFFFAOYSA-N 0.000 claims 1
- PPJPCHRLGTVRBJ-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-7-(4-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C1CN(C)CCN1C(C(=C1C=2C(=CC=C(F)C=2)Br)CN)=NC2=C1C(=O)N(C)C(=O)N2C PPJPCHRLGTVRBJ-UHFFFAOYSA-N 0.000 claims 1
- VDWGTMUMUISEGS-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-7-(methylamino)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(NC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC(F)=CC=C1Br VDWGTMUMUISEGS-UHFFFAOYSA-N 0.000 claims 1
- CXIIQRMCLKMMJF-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-7-(pyridin-4-ylmethylamino)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(C=2C(=CC=C(F)C=2)Br)=C2C(=O)N(C)C(=O)N(C)C2=NC=1NCC1=CC=NC=C1 CXIIQRMCLKMMJF-UHFFFAOYSA-N 0.000 claims 1
- PTGQTILYRYFWNL-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-7-morpholin-4-ylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(C=2C(=CC=C(F)C=2)Br)=C2C(=O)N(C)C(=O)N(C)C2=NC=1N1CCOCC1 PTGQTILYRYFWNL-UHFFFAOYSA-N 0.000 claims 1
- UHYAYBQYODCACG-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1,3-dimethyl-8h-pyrido[2,3-d]pyrimidine-2,4,7-trione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(O)=C(CN)C=1C1=CC(F)=CC=C1Br UHYAYBQYODCACG-UHFFFAOYSA-N 0.000 claims 1
- KWUIPYRTIGQIQH-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-7-(diethylamino)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(N(CC)CC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC(F)=CC=C1Br KWUIPYRTIGQIQH-UHFFFAOYSA-N 0.000 claims 1
- PXXXJKLIYAELBV-UHFFFAOYSA-N 6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-7-(ethylamino)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(NCC)=NC=2N(C)C(=O)N(C)C(=O)C=2C=1C1=CC(F)=CC=C1Br PXXXJKLIYAELBV-UHFFFAOYSA-N 0.000 claims 1
- LSLOGTFSQHTFRR-UHFFFAOYSA-N 6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-1,3-dimethyl-7-(trifluoromethyl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=C(F)C=C(F)C=C1C1=C(CN)C(C(F)(F)F)=NC2=C1C(=O)N(C)C(=O)N2C LSLOGTFSQHTFRR-UHFFFAOYSA-N 0.000 claims 1
- KWYFMUCKFHCEFP-UHFFFAOYSA-N 6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-2-(dimethylamino)-3-methyl-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-one Chemical compound COC1=C(F)C=C(F)C=C1C1=C(CN)C(C(F)(F)F)=NC2=C1C(=O)N(C)C(N(C)C)=N2 KWYFMUCKFHCEFP-UHFFFAOYSA-N 0.000 claims 1
- YVKBGMDKVVVPBK-UHFFFAOYSA-N 6-(aminomethyl)-5-(3,5-difluoro-2-methoxyphenyl)-3-methyl-2-(methylamino)-7-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-one Chemical compound C=12C(=O)N(C)C(NC)=NC2=NC(C(F)(F)F)=C(CN)C=1C1=CC(F)=CC(F)=C1OC YVKBGMDKVVVPBK-UHFFFAOYSA-N 0.000 claims 1
- AZMCIAMRJIHRFZ-UHFFFAOYSA-N 6-(aminomethyl)-5-(4-chloro-2-methoxyphenyl)-1,3,7-trimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=CC(Cl)=CC=C1C1=C(CN)C(C)=NC2=C1C(=O)N(C)C(=O)N2C AZMCIAMRJIHRFZ-UHFFFAOYSA-N 0.000 claims 1
- ABANWMZTDDAKEH-UHFFFAOYSA-N 6-(aminomethyl)-5-(5-fluoro-2-methoxyphenyl)-1,3-dimethyl-7-morpholin-4-ylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=CC=C(F)C=C1C1=C(CN)C(N2CCOCC2)=NC2=C1C(=O)N(C)C(=O)N2C ABANWMZTDDAKEH-UHFFFAOYSA-N 0.000 claims 1
- JQQOLNZRFCWMRZ-UHFFFAOYSA-N 6-(aminomethyl)-7-(cyclopropylmethylamino)-5-(2,4-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound NCC=1C(C=2C(=CC(Cl)=CC=2)Cl)=C2C(=O)N(C)C(=O)N(C)C2=NC=1NCC1CC1 JQQOLNZRFCWMRZ-UHFFFAOYSA-N 0.000 claims 1
- WFTDPRDHZSJQCE-UHFFFAOYSA-N 6-(aminomethyl)-7-[bis(2,2-difluoroethyl)amino]-5-(2-bromo-5-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N(CC(F)F)CC(F)F)=C(CN)C=1C1=CC(F)=CC=C1Br WFTDPRDHZSJQCE-UHFFFAOYSA-N 0.000 claims 1
- UYLKKDOQGIKGFR-UHFFFAOYSA-N 6-(aminomethyl)-7-chloro-5-(2,4-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(Cl)=C(CN)C=1C1=CC=C(Cl)C=C1Cl UYLKKDOQGIKGFR-UHFFFAOYSA-N 0.000 claims 1
- AUGQLMNHLALSNI-UHFFFAOYSA-N 7-amino-5-(2,5-dichlorophenyl)-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(C#N)C=1C1=CC(Cl)=CC=C1Cl AUGQLMNHLALSNI-UHFFFAOYSA-N 0.000 claims 1
- IVZLPHVERJFCTF-UHFFFAOYSA-N 7-amino-5-[2-(aminomethyl)phenyl]-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(C#N)C=1C1=CC=CC=C1CN IVZLPHVERJFCTF-UHFFFAOYSA-N 0.000 claims 1
- YEWACWFQUSSPGZ-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-1,3-dimethyl-5-(3-methyl-1-benzothiophen-2-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(N)C(CN)=C2C1=C(C)C2=CC=CC=C2S1 YEWACWFQUSSPGZ-UHFFFAOYSA-N 0.000 claims 1
- HEMHQMJOXSBMLV-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-1,3-dimethyl-5-(3-methylimidazol-4-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound CN1C=NC=C1C1=C(CN)C(N)=NC2=C1C(=O)N(C)C(=O)N2C HEMHQMJOXSBMLV-UHFFFAOYSA-N 0.000 claims 1
- QVTZKWQWDHVEQE-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-1,3-dimethyl-5-(3-methylthiophen-2-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C1=CSC(C=2C=3C(=O)N(C)C(=O)N(C)C=3N=C(N)C=2CN)=C1C QVTZKWQWDHVEQE-UHFFFAOYSA-N 0.000 claims 1
- LAMTXHIPLANNMZ-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-1,3-dimethyl-5-phenylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC=C1 LAMTXHIPLANNMZ-UHFFFAOYSA-N 0.000 claims 1
- ZISJVMLZPSLHLL-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-1,3-dimethyl-5-pyridin-3-ylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CN=C1 ZISJVMLZPSLHLL-UHFFFAOYSA-N 0.000 claims 1
- AZJSHYDXUSPRKU-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(1-benzothiophen-2-yl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C1=CC=C2SC(C=3C(CN)=C(N)N=C4N(C(N(C)C(=O)C4=3)=O)C)=CC2=C1 AZJSHYDXUSPRKU-UHFFFAOYSA-N 0.000 claims 1
- IEECBPIXCYEOMZ-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2,3-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC(Cl)=C1Cl IEECBPIXCYEOMZ-UHFFFAOYSA-N 0.000 claims 1
- AGNXPCJOXZWVEM-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2,4-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(Cl)C=C1Cl AGNXPCJOXZWVEM-UHFFFAOYSA-N 0.000 claims 1
- ZZMFKRCEUICKCC-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2,4-dichlorophenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)NC(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(Cl)C=C1Cl ZZMFKRCEUICKCC-UHFFFAOYSA-N 0.000 claims 1
- PVBIBWAMBOYUKT-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2,5-dichlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(Cl)=CC=C1Cl PVBIBWAMBOYUKT-UHFFFAOYSA-N 0.000 claims 1
- SWFXDSGRJVGVPA-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-bromo-4-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(F)C=C1Br SWFXDSGRJVGVPA-UHFFFAOYSA-N 0.000 claims 1
- VQUGCZZIQOITQY-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-bromo-5-fluorophenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)NC(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1Br VQUGCZZIQOITQY-UHFFFAOYSA-N 0.000 claims 1
- JGBNONXELAWFNR-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-bromophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC=C1Br JGBNONXELAWFNR-UHFFFAOYSA-N 0.000 claims 1
- KFPUEKAWTWGYSE-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-3,6-difluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=C(F)C=CC(F)=C1Cl KFPUEKAWTWGYSE-UHFFFAOYSA-N 0.000 claims 1
- UHNMHNGJRWJHOQ-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-4-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(F)C=C1Cl UHNMHNGJRWJHOQ-UHFFFAOYSA-N 0.000 claims 1
- CWVMUGTZEHWAPH-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1Cl CWVMUGTZEHWAPH-UHFFFAOYSA-N 0.000 claims 1
- FECFEBLXCJQTCL-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)NC(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1Cl FECFEBLXCJQTCL-UHFFFAOYSA-N 0.000 claims 1
- VPBDZQQYZJRTQA-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-5-fluorophenyl)-3-methyl-1h-pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)NC2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1Cl VPBDZQQYZJRTQA-UHFFFAOYSA-N 0.000 claims 1
- LZXAZLHSWWCSQN-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chloro-6-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=C(F)C=CC=C1Cl LZXAZLHSWWCSQN-UHFFFAOYSA-N 0.000 claims 1
- IPGCEACLSSMOTO-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-chlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC=C1Cl IPGCEACLSSMOTO-UHFFFAOYSA-N 0.000 claims 1
- CMTNDUWGFAHFSE-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(2-methoxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=CC=CC=C1C1=C(CN)C(N)=NC2=C1C(=O)N(C)C(=O)N2C CMTNDUWGFAHFSE-UHFFFAOYSA-N 0.000 claims 1
- BNZFBNLUDQGRML-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(3-bromothiophen-2-yl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C=1SC=CC=1Br BNZFBNLUDQGRML-UHFFFAOYSA-N 0.000 claims 1
- WXWFNEBRVXUMEU-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(3-methoxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound COC1=CC=CC(C=2C=3C(=O)N(C)C(=O)N(C)C=3N=C(N)C=2CN)=C1 WXWFNEBRVXUMEU-UHFFFAOYSA-N 0.000 claims 1
- FVXMPFZFKBTJHB-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(4,5-dimethylthiophen-2-yl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound S1C(C)=C(C)C=C1C1=C(CN)C(N)=NC2=C1C(=O)N(C)C(=O)N2C FVXMPFZFKBTJHB-UHFFFAOYSA-N 0.000 claims 1
- GUISYUQVTXSKOA-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(4-bromophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(Br)C=C1 GUISYUQVTXSKOA-UHFFFAOYSA-N 0.000 claims 1
- CHZHICHLKIKQNV-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(4-fluorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(F)C=C1 CHZHICHLKIKQNV-UHFFFAOYSA-N 0.000 claims 1
- FKYJNXDPFFBMAE-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(5-chlorothiophen-2-yl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=C(Cl)S1 FKYJNXDPFFBMAE-UHFFFAOYSA-N 0.000 claims 1
- KAQXHBSTWIXVRR-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-(5-fluoro-2-nitrophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(F)=CC=C1[N+]([O-])=O KAQXHBSTWIXVRR-UHFFFAOYSA-N 0.000 claims 1
- DMKOWQUDOKVXTD-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-[2-(aminomethyl)phenyl]-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC=CC=C1CN DMKOWQUDOKVXTD-UHFFFAOYSA-N 0.000 claims 1
- JVBDUTVTEFUCLX-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-[2-chloro-5-(trifluoromethyl)phenyl]-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1=CC(C(F)(F)F)=CC=C1Cl JVBDUTVTEFUCLX-UHFFFAOYSA-N 0.000 claims 1
- CJGPHBUMEOVUML-UHFFFAOYSA-N 7-amino-6-(aminomethyl)-5-cyclopentyl-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C=12C(=O)N(C)C(=O)N(C)C2=NC(N)=C(CN)C=1C1CCCC1 CJGPHBUMEOVUML-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- YSQDDBGBWAZFBE-UHFFFAOYSA-N N-amino-1-azanylidyne-N-nitromethanesulfonothioamide Chemical compound [O-][N+](=O)N(N)S(=O)(=S)C#N YSQDDBGBWAZFBE-UHFFFAOYSA-N 0.000 claims 1
- ZXXVTWGLRDSEKS-UHFFFAOYSA-N NNS(=O)(=S)[N+]([O-])=O Chemical compound NNS(=O)(=S)[N+]([O-])=O ZXXVTWGLRDSEKS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005216 haloheteroaryl group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- TVHKJGCQXIKPRF-UHFFFAOYSA-N n-[6-(aminomethyl)-5-(4-chloro-2-methoxyphenyl)-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidin-7-yl]methanesulfonamide Chemical compound COC1=CC(Cl)=CC=C1C1=C(CN)C(NS(C)(=O)=O)=NC2=C1C(=O)N(C)C(=O)N2C TVHKJGCQXIKPRF-UHFFFAOYSA-N 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 CS(C)C1=BB=B*1 Chemical compound CS(C)C1=BB=B*1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58857704P | 2004-07-16 | 2004-07-16 | |
| US60/588,577 | 2004-07-16 | ||
| PCT/US2005/025153 WO2006020017A2 (en) | 2004-07-16 | 2005-07-15 | Dipeptidyl peptidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008506708A JP2008506708A (ja) | 2008-03-06 |
| JP2008506708A5 true JP2008506708A5 (https=) | 2008-09-04 |
| JP4945443B2 JP4945443B2 (ja) | 2012-06-06 |
Family
ID=35505925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007521673A Expired - Fee Related JP4945443B2 (ja) | 2004-07-16 | 2005-07-15 | ジペプチジルぺプチダーゼ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7825242B2 (https=) |
| EP (1) | EP1773832A2 (https=) |
| JP (1) | JP4945443B2 (https=) |
| WO (2) | WO2006019965A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| SG10201404220TA (en) | 2006-04-11 | 2014-10-30 | Arena Pharm Inc | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| WO2008064107A2 (en) * | 2006-11-20 | 2008-05-29 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008073958A2 (en) * | 2006-12-12 | 2008-06-19 | Wyeth | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| US8236950B2 (en) * | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US8133898B2 (en) | 2007-03-30 | 2012-03-13 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2011143521A2 (en) * | 2010-05-13 | 2011-11-17 | Dara Biosciences, Inc. | Enhanced homing and engraftment of hematopoietic stem cells using cd26 inhibitors |
| EP2582673B1 (de) * | 2010-06-15 | 2014-08-06 | Bayer Intellectual Property GmbH | Verfahren zur herstellung von 2,2-difluorethylamin-derivaten durch alkylierung mit 2,2- difluor-1-halogenethanen |
| US8907086B2 (en) | 2011-03-03 | 2014-12-09 | Merck Sharp & Dohme Corp. | Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| JP6876833B2 (ja) * | 2017-02-27 | 2021-05-26 | ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｆｇｆｒ阻害剤およびその使用 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US10100054B1 (en) | 2018-04-03 | 2018-10-16 | King Saud University | Pyrido[2,3-d]pyrimidines as anticancer agents |
Family Cites Families (255)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
| US3947442A (en) * | 1969-11-20 | 1976-03-30 | The Sherwin-Williams Company | Method for producing heterocyclic acid anhydrides and pyrimidinediones |
| US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| US4113859A (en) * | 1972-10-12 | 1978-09-12 | Burroughs Wellcome Co. | Certain pyrido-pyrimidines for treating mammalian and avian infections |
| US3922275A (en) * | 1972-11-09 | 1975-11-25 | Hisamitsu Pharmaceutical Co | Pyrido{8 2,3-D{9 {0 pyrimidine-2,4(1H,3H)-diones |
| US4494978A (en) | 1976-12-30 | 1985-01-22 | Chevron Research Company | Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides |
| US4808587A (en) * | 1986-04-16 | 1989-02-28 | Nippon Zoki Pharmaceutical Co., Ltd. | 5-substituted pyrido[2,3-d]pyrimidine-2,4-diones |
| ES2031513T3 (es) * | 1986-08-21 | 1992-12-16 | Pfizer Inc. | Quinazolindionas y piridopirimidinadionas. |
| US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| AU618158B2 (en) * | 1989-01-07 | 1991-12-12 | Bayer Aktiengesellschaft | New substituted pyrido(2,3-d)pyrimidines |
| US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| US5366862A (en) | 1990-02-14 | 1994-11-22 | Receptor Laboratories, Inc. | Method for generating and screening useful peptides |
| US5814460A (en) | 1990-02-14 | 1998-09-29 | Diatide, Inc. | Method for generating and screening useful peptides |
| US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| DE4110019C2 (de) | 1991-03-27 | 2000-04-13 | Merck Patent Gmbh | Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| US5387512A (en) | 1991-06-07 | 1995-02-07 | Merck & Co. Inc. | Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| ES2153831T3 (es) | 1991-10-22 | 2001-03-16 | New England Medical Center Inc | Inhibidores de dipeptidil-aminopeptidasa de tipo iv. |
| US5342843A (en) | 1991-12-12 | 1994-08-30 | Kyowa Hakko Kogyo Co., Ltd. | Thienoimidazoppyridone derivatives |
| DE4141788A1 (de) | 1991-12-18 | 1993-06-24 | Merck Patent Gmbh | Imidazopyridine |
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| DE4305602A1 (de) | 1992-06-17 | 1993-12-23 | Merck Patent Gmbh | Imidazopyridine |
| IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| TW299333B (https=) * | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
| US5811281A (en) | 1993-07-12 | 1998-09-22 | Cornell Research Foundation, Inc. | Immortalized intestinal epithelial cell lines |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE4341453A1 (de) | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
| US5798344A (en) | 1994-03-08 | 1998-08-25 | Otsuka Pharmaceutical Factory, Inc. | Phosphonic ester derivatives of quinazolinones |
| US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| EP0764151A2 (en) | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
| US5589437A (en) | 1994-06-13 | 1996-12-31 | Vichnevetskaia; Klara D. | Method of using 5-hydroxybenzimidazole compounds for reducing transpiration in plants |
| US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
| DE4432860A1 (de) | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| US6325989B1 (en) | 1995-06-01 | 2001-12-04 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum |
| US6265551B1 (en) | 1995-06-01 | 2001-07-24 | Dana-Farber Cancer Institute, Inc. | Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof |
| JPH0928376A (ja) | 1995-07-21 | 1997-02-04 | Ajinomoto Co Inc | 新規ジペプチジルペプチダーゼｉｖとその製造方法 |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
| US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| US5885997A (en) | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| CZ298812B6 (cs) | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| DE69840230D1 (de) | 1997-05-16 | 2009-01-02 | Novozymes Inc | Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren |
| EP0897012A1 (en) | 1997-07-05 | 1999-02-17 | Societe Des Produits Nestle S.A. | Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae |
| US6235493B1 (en) | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
| CA2304206A1 (en) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
| US6485955B1 (en) | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| SI1028950T1 (en) * | 1997-10-28 | 2003-08-31 | Warner-Lambert Company Llc | 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
| ATE319818T1 (de) | 1997-12-16 | 2006-03-15 | Novozymes As | Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| US20020061839A1 (en) | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2331122A1 (en) | 1998-05-04 | 1999-11-11 | Point Therapeutics, Inc. | Hematopoietic stimulation |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| AU765370B2 (en) | 1998-06-05 | 2003-09-18 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| US6129911A (en) | 1998-07-10 | 2000-10-10 | Rhode Island Hospital, A Lifespan Partner | Liver stem cell |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| JP2000119272A (ja) * | 1998-10-15 | 2000-04-25 | Nippon Zoki Pharmaceut Co Ltd | 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体 |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| JP2002542246A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| DE19926233C1 (de) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
| USRE40876E1 (en) | 1999-06-21 | 2009-08-18 | Eli Lilly And Company | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| ES2269178T3 (es) | 1999-09-10 | 2007-04-01 | The University Of Sydney | Dipeptidil peptidasas. |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6251391B1 (en) | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
| US6261794B1 (en) | 1999-10-14 | 2001-07-17 | Saint Louis University | Methods for identifying inhibitors of methionine aminopeptidases |
| US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| EP1228061A4 (en) | 1999-11-12 | 2004-12-15 | Guilford Pharm Inc | DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| PT1741446E (pt) | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| CN1425008A (zh) * | 2000-01-24 | 2003-06-18 | 沃尼尔·朗伯公司 | 3－氨基喹唑啉－2,4－二酮抗菌剂 |
| US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| US7064145B2 (en) | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| HU229042B1 (en) | 2000-03-31 | 2013-07-29 | Prosidion Ltd | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| DE10025464A1 (de) | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen |
| WO2001092493A2 (en) | 2000-05-26 | 2001-12-06 | Millennium Pharmaceuticals, Inc. | 21956 and 25856, human aminopeptidases and uses thereof |
| US6783757B2 (en) | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| ZA200300255B (en) | 2000-07-20 | 2004-09-28 | Bristol Myers Squibb Pharma Co | Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors. |
| WO2002010139A1 (en) | 2000-08-01 | 2002-02-07 | Pharmacia Corporation | Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| CA2417942C (en) | 2000-08-04 | 2010-06-29 | Warner-Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| US7074794B2 (en) | 2000-08-10 | 2006-07-11 | Mitsubishi Pharma Corporation | Proline derivatives and the use thereof as drugs |
| US20020165237A1 (en) | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
| US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| CA2422162C (en) | 2000-09-09 | 2012-10-23 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
| US7138397B2 (en) | 2000-10-06 | 2006-11-21 | Tanabe Seiyaku Co., Ltd. | Nitrogenous 5-membered ring compounds |
| CZ20031301A3 (cs) | 2000-10-12 | 2003-10-15 | Ferring Bv | Izolovaná nukleová kyselina, polypeptid, expresní vektor a protilátka |
| KR20030096227A (ko) | 2000-10-27 | 2003-12-24 | 프로비오드룩 아게 | 신경 및 신경정신 질환의 치료방법 |
| AUPR107800A0 (en) | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
| MXPA03003870A (es) | 2000-10-30 | 2004-08-12 | Johnson & Johnson | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. |
| WO2002059343A2 (en) | 2000-10-31 | 2002-08-01 | Vanderbilt University | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema |
| WO2002038742A2 (en) | 2000-11-08 | 2002-05-16 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
| US20020155565A1 (en) | 2000-11-10 | 2002-10-24 | Pilar Garin-Chesa | FAP-activated anti-tumor compounds |
| US20030055052A1 (en) | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| US6670380B2 (en) | 2000-11-20 | 2003-12-30 | Bristol-Myers Squibb Co. | Pyridone inhibitors of fatty acid binding protein and method |
| MXPA03005152A (es) | 2000-12-11 | 2004-10-14 | Tularik Inc | Antogonista de cxcr3. |
| WO2002051836A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| JP2004520330A (ja) | 2001-01-02 | 2004-07-08 | インスティテュート ヒューア メディツィンテクノロギー マグデブルク ゲーエムベーハー イーエムテーエム | 動脈硬化症の治療と予防的治療、ゲル−クームズ分類ｉ型のアレルギー反応の治療と予防、ならびに、毛包性および表皮性の過角化症とケラチノサイトの促進された増殖を伴う皮膚病の治療と予防のための、酵素阻害因子およびその薬剤化合物の併用 |
| DE10100053A1 (de) | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
| GB0101760D0 (en) | 2001-01-23 | 2001-03-07 | Glaxo Group Ltd | Novel protein |
| CN1500080A (zh) | 2001-02-02 | 2004-05-26 | ����ҩƷ��ҵ��ʽ���� | 稠合杂环化合物 |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| KR100926247B1 (ko) | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
| US6337069B1 (en) | 2001-02-28 | 2002-01-08 | B.M.R.A. Corporation B.V. | Method of treating rhinitis or sinusitis by intranasally administering a peptidase |
| SK287334B6 (sk) | 2001-03-19 | 2010-07-07 | Novartis Ag | Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie |
| US7915264B2 (en) * | 2001-03-26 | 2011-03-29 | Novartis Ag | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
| ATE395912T1 (de) | 2001-03-27 | 2008-06-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE10115921A1 (de) | 2001-03-30 | 2002-10-02 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen |
| US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| PE20021080A1 (es) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030060494A1 (en) | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| RU2299066C2 (ru) | 2001-06-27 | 2007-05-20 | Пробиодруг Аг | Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов |
| ES2296979T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| CA2418543A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| DE60221983T2 (de) | 2001-06-27 | 2008-05-15 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| US20030135023A1 (en) | 2001-06-27 | 2003-07-17 | Hans-Ulrich Demuth | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| WO2003007888A2 (en) | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| AU2002328946A1 (en) | 2001-08-13 | 2003-03-03 | Probiodrug Ag | Irreversible cysteine protease inhibitors of legumain |
| US9048965B2 (en) | 2001-08-24 | 2015-06-02 | Mark Henrik Sandstrom | Input-controllable dynamic cross-connect |
| DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
| US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| WO2003024942A1 (en) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Thiazolidine derivative and medicinal use thereof |
| US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
| EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| CA2461202C (en) | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| CA2462112A1 (en) | 2001-10-01 | 2003-04-10 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
| WO2003030946A1 (en) | 2001-10-09 | 2003-04-17 | Novartis Ag | Regulation of insulin production |
| US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| EP1442028A4 (en) | 2001-11-06 | 2009-11-04 | Bristol Myers Squibb Co | SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS |
| US20030125304A1 (en) | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
| WO2003045228A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
| EP1469873A4 (en) | 2001-11-26 | 2007-10-03 | Tufts College | PEPTIDOMIMETIC INHIBITORS FROM BEHIND PROLIN SPLENDING ENZYMES |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| KR20040068240A (ko) | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| JP2005516968A (ja) | 2001-12-29 | 2005-06-09 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用 |
| JP2005513165A (ja) | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物 |
| AU2003218969A1 (en) | 2002-02-01 | 2003-09-02 | Probiodrug Ag | Modulation of t lymphocytes using dp iv inhibitors |
| US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| ES2252656T3 (es) | 2002-02-13 | 2006-05-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y quinolina. |
| KR100608414B1 (ko) | 2002-02-13 | 2006-08-02 | 에프. 호프만-라 로슈 아게 | 신규한 피리딘- 및 피리미딘-유도체 |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| JP2005527504A (ja) | 2002-02-28 | 2005-09-15 | プロシディオン・リミテッド | グルタミニルを基礎するｄｐｉｖ阻害剤 |
| ES2361403T3 (es) | 2002-03-07 | 2011-06-16 | X-Ceptor Therapeutics, Inc. | Moduladores de quinazolinona de receptores nucleares. |
| US6947847B2 (en) | 2002-03-08 | 2005-09-20 | Wisconsin Alumni Research Foundation | Method to design therapeutically important compounds |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20040106802A1 (en) | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
| BR0308816A (pt) | 2002-04-08 | 2005-03-22 | Torrent Pharmaceuticals Ltd | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas |
| AU2003228793B2 (en) | 2002-04-30 | 2008-01-03 | Trustees Of Tufts College | Smart Pro-Drugs of Serine Protease Inhibitors |
| TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| WO2003099818A1 (en) | 2002-05-23 | 2003-12-04 | Chiron Corporation | Substituted quinazolinone compounds |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| MXPA04012226A (es) | 2002-06-06 | 2005-04-08 | Eisai Co Ltd | Nuevos derivados de imidazola. |
| WO2003106628A2 (en) | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
| US20040054171A1 (en) | 2002-07-04 | 2004-03-18 | Jensen Anette Frost | Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative |
| ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| EP1528931B1 (en) | 2002-08-09 | 2008-05-07 | Prosidion Ltd. | Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE10238470A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| WO2004031374A2 (en) | 2002-09-18 | 2004-04-15 | Prosidion Ltd. | Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| US20040058876A1 (en) | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
| US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US6869966B2 (en) | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| KR20050067418A (ko) | 2002-10-18 | 2005-07-01 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제 |
| US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
| DE60332856D1 (de) | 2002-10-23 | 2010-07-15 | Bristol Myers Squibb Co | Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| EP1565437A1 (en) | 2002-11-18 | 2005-08-24 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7109192B2 (en) | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
| UY28103A1 (es) * | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| US20050014732A1 (en) | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR20110059664A (ko) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| US20040229848A1 (en) | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
| WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| RU2339636C2 (ru) | 2003-06-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг | Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv) |
| ES2355105T3 (es) | 2003-06-20 | 2011-03-22 | F. Hoffmann-La Roche Ag | Pirido(2,1-a)isoquinolina como inhibidores de la dpp-iv. |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
-
2005
- 2005-07-14 WO PCT/US2005/025070 patent/WO2006019965A2/en not_active Ceased
- 2005-07-15 EP EP05772260A patent/EP1773832A2/en not_active Withdrawn
- 2005-07-15 US US11/183,335 patent/US7825242B2/en not_active Expired - Fee Related
- 2005-07-15 WO PCT/US2005/025153 patent/WO2006020017A2/en not_active Ceased
- 2005-07-15 JP JP2007521673A patent/JP4945443B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008506708A5 (https=) | ||
| JP2007314551A5 (https=) | ||
| AU2004235907B2 (en) | Fused pyrimidine derivatives with CRF activity | |
| US10238660B2 (en) | Organic compounds | |
| ES2271221T3 (es) | Derivados imidazo-pirimidina como ligandos para receptores gaba. | |
| US8338435B2 (en) | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | |
| US8697710B2 (en) | Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones | |
| US8637531B2 (en) | Pyrido(3,2-d)pyridmidines useful for treating viral infections | |
| US20120136013A1 (en) | Organic compounds | |
| US20030104974A1 (en) | Dual inhibitorsof PDE 7 and PDE 4 | |
| PT2016080E (pt) | Derivados da di-hidropirazolopirimidinona | |
| JP2005502683A5 (https=) | ||
| CA2740391A1 (en) | Organic compounds | |
| CA2559302A1 (en) | 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors | |
| KR20140059195A (ko) | 트리시클릭 헤테로시클릭 화합물 및 jak 저해제 | |
| KR20060110006A (ko) | 비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물 | |
| AU2011258005A1 (en) | Heterocyclic compounds as Janus kinase inhibitors | |
| TW200920372A (en) | Anti-viral compounds, compositions, and methods of use | |
| US6395766B1 (en) | Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition | |
| ES2689325T3 (es) | Derivados de carbamoilo de carbonilamino-pirazoles bicíclicos como pro-fármacos | |
| JP2022534501A (ja) | 三環式化合物 | |
| CA2906137A1 (en) | Novel protein kinase inhibitors | |
| Salem et al. | A review on Synthesis and Biological Evaluations of Pyrazolo [3, 4-d] pyrimidine Schaffold | |
| AU2023255673A1 (en) | Bicyclic compounds | |
| RU2024121326A (ru) | Новые противовирусные производные триазола, их синтез и применение для лечения вирусных инфекций млекопитающих |